BRCA carrier status as a prognostic factor for prostate cancer

Retrospective study of optimal treatment for intermediate-risk testes cancer

Open Window project improves patient quality of life

Role of family history and genetic testing in diagnosis

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Advances in myeloma

Problems in the structure of clinical trials

New approaches to personalised medicine

Heterogeneity of tumours and the challenges of biomarker development

Cancer genes differ in different parts of a tumour

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer

Endocrine therapy resistance and next generation sequencing